- Home
- AWH vs SNGX Comparison
AWH vs SNGX Comparison
Compare AWH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- SNGX
- Stock Information
- Founded
- AWH 1993
- SNGX 1987
- Country
- AWH United States
- SNGX United States
- Employees
- AWH N/A
- SNGX N/A
- Industry
- AWH Medical/Dental Instruments
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- AWH Health Care
- SNGX Health Care
- Exchange
- AWH Nasdaq
- SNGX Nasdaq
- Market Cap
- AWH 11.7M
- SNGX 9.6M
- IPO Year
- AWH N/A
- SNGX 1987
- Fundamental
- Price
- AWH $0.81
- SNGX $3.12
- Analyst Decision
- AWH Buy
- SNGX
- Analyst Count
- AWH 2
- SNGX 0
- Target Price
- AWH $4.40
- SNGX N/A
- AVG Volume (30 Days)
- AWH 76.2K
- SNGX 45.6K
- Earning Date
- AWH 11-14-2024
- SNGX 11-08-2024
- Dividend Yield
- AWH N/A
- SNGX N/A
- EPS Growth
- AWH N/A
- SNGX N/A
- EPS
- AWH N/A
- SNGX N/A
- Revenue
- AWH $8,963,000.00
- SNGX $364,183.00
- Revenue This Year
- AWH $11.87
- SNGX N/A
- Revenue Next Year
- AWH $79.10
- SNGX $76.64
- P/E Ratio
- AWH N/A
- SNGX N/A
- Revenue Growth
- AWH N/A
- SNGX N/A
- 52 Week Low
- AWH $0.67
- SNGX $1.83
- 52 Week High
- AWH $5.65
- SNGX $19.20
- Technical
- Relative Strength Index (RSI)
- AWH 50.69
- SNGX 40.25
- Support Level
- AWH $0.68
- SNGX $2.93
- Resistance Level
- AWH $0.90
- SNGX $3.35
- Average True Range (ATR)
- AWH 0.07
- SNGX 0.19
- MACD
- AWH 0.00
- SNGX -0.01
- Stochastic Oscillator
- AWH 49.09
- SNGX 32.26
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).